Pricing Log in Create free account
Saturday 17 October 2026 Export CTKB’s income statement to Excel — free account

Cytek Biosciences, Inc.

CTKB Healthcare Medical Devices

Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024. In the quarter to June 2026, revenue grew 5.57%, EPS fell 125.0%, free cash flow grew 42.5% and total debt fell 68.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

5.24 0.17 −3.14%
Market cap
$703.2M
P/E
0.0×
Fwd P/E
−11.7×
Dividend yield
—
F-score
4/9
Altman Z
3.89
Beneish M
−3.30
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 8.11%

Capital & Financial Ratios $m

Market Cap 703.21
Revenue 206.71
Net Income (80.58)
Free Cash Flow (11.97)
Net Debt (261.76)
Current Ratio 4.48 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (11.70) (negative: loss-making)
P/S ratio 3.28
P/B ratio 2.11
Past 5Y EPS Growth —
This Y EPS Growth 33.97% (at or above 15%: strong)
Next Y EPS Growth 25.24% (at or above 15%: strong)
Next Y revenue growth 3.92%
Next 5Y EPS Growth 25.50% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.0×, against a ten-year median of 3.0×; over the ten years it ranged from 0.5× in 2025 to 18.3× in 2021.
P/S against its own 10 years 28.90%
10-year low 10-year high
P/B against its own 10 years 47.83%
10-year low 10-year high
EV/Sales against its own 10 years 31.56%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 263 278 262 262
Receivables 56 61 63 50
Inventory 61 44 48 52
Other — — — —
392 396 392 378
2023 2024 2025 Q'26
Payables 3 6 6 8
ST’ Debt — — — —
Other 10 15 19 23
56 68 78 84

Compound Annual Growth %

10y 5y 3y
Sales — 16.76% 7.10%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 13.90% (7.05%)

Revenue $m

Mar Jun Sep Dec Year
’26 44 48 — — —
’25 41 46 52 62 201
’24 45 47 52 57 200
’23 37 50 48 58 193
’22 35 40 40 48 164
’21 24 30 34 39 128
’20 18 19 25 — 93
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) 1 — — —
’25 0 0 (4) (1) (5)
’24 4 6 13 2 25
’23 3 (3) (4) 10 5
’22 (1) (9) (8) 6 (12)
’21 2 (4) 1 5 5
’20 1 1 2 12 15
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (1) — — —
’25 (1) (2) (5) (2) (9)
’24 3 5 12 1 22
’23 2 (4) (6) 8 0
’22 (2) (11) (9) 0 (22)
’21 1 (5) 0 4 0
’20 1 0 2 11 14
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.15) (0.09) — — —
’25 (0.09) (0.04) (0.04) (0.34) (0.52)
’24 (0.05) (0.08) 0.01 0.07 (0.05)
’23 (0.05) (0.03) (0.05) 0.04 (0.09)
’22 (0.02) (0.01) 0.01 0.03 0.02
’21 0.00 0.00 0.00 0.00 0.00
’20 (0.01) 0.26 0.21 — 0.60
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 15.91 7.38 3.80 4.66 2.37

Analyst estimates 2026–2028

Powerpack
High — — — — — 28.70 17.41 13.77 9.33 7.30
People
People Employees — — — — — 502 583 676 648 702
Revenue/emp, $m — — — 0.00 0.00 0.25 0.28 0.29 0.31 0.29
Income, $m
Income, $m Revenue — — — 58 93 128 164 193 200 201
Gross margin, % — — — 49.54 55.70 61.86 61.56 56.69 55.43 51.84
EBT — — — (16) 14 6 1 (16) (6) (30)
EBT margin, % — — — (28.15) 15.54 4.64 0.77 (8.14) (2.84) (14.81)
Net income — 0 — (17) 19 3 2 (12) (6) (67)
Depreciation — — — 0 1 1 6 9 10 12
Per share, $
Per share, $ Revenue — — — 0.44 3.19 1.67 1.22 1.43 1.53 1.58
Earnings — — — (0.13) 0.67 0.00 0.02 (0.09) (0.05) (0.52)
Cash flow — — — (0.10) 0.52 0.06 (0.09) 0.04 0.19 (0.04)
Capex — — — 0.00 (0.05) (0.06) (0.07) (0.04) (0.03) (0.03)
Free cash flow — — — (0.10) 0.47 0.00 (0.16) 0.00 0.17 (0.07)
Book value — — — 0.25 6.12 5.28 3.16 2.91 3.03 2.68
Shares, m — — — 133 29 77 135 135 131 128
Valuation, ×
Valuation, × P/E — — — 36.38 36.38 5,100.00 541.18 0.00 0.00 0.00
P/S — — — 6.05 6.05 9.79 8.30 6.22 4.23 3.20
P/B — — — 0.00 0.00 3.09 3.20 3.05 2.14 1.89
EV/Sales — — — 4.43 4.43 6.94 6.21 4.86 2.85 1.91
EV/FCF — — — 46.54 46.54 3,337.63 (46.38) 2,510.34 26.02 (44.54)
Cash, $m
Cash, $m Operating cash flow — — — (14) 15 5 (12) 5 25 (5)
Capex — — — (1) (2) (4) (10) (5) (3) (4)
Free cash flow — — — (14) 14 0 (22) 0 22 (9)
Balance, $m
Balance, $m Working capital — — — 47 182 399 405 336 329 314
Total debt — — — — 3 — 2 2 1 1
Net debt — — — (30) (166) (365) (342) (261) (277) (261)
Shareholders’ equity — — — 33 178 405 426 393 396 342
Returns, %
Returns, % ROA — — — (47.41) 2.21 0.00 0.52 (2.40) (1.21) (13.85)
ROIC — — — 0.00 70.14 14.04 (1.35) (13.19) (10.79) (31.26)
ROE — — — 58.30 (11.14) 0.00 0.62 (2.97) (1.53) (18.05)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Cytek Biosciences, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BBNX Beta Bionics, Inc. $933.8M — (loss-making) — (loss-making) +37.76% (above 0%: growing) n/m −1.87% (below 0%: shrinking) 59.04% (79.90%) Compare
SIBN SiBone $892.3M — (loss-making) — (loss-making) +15.18% (above 0%: growing) n/m +60.12% (above 0%: growing) 79.54% (8.58%) Compare
AHCO AdaptHealth Corp. $871.2M — (loss-making) 13.2× +12.66% (above 0%: growing) n/m −128.56% (below 0%: shrinking) 14.08% (18.61%) Compare
INMD InMode Ltd. $824.0M 11.3× 11.8× −0.01% (below 0%: shrinking) −30.95% (below 0%: shrinking) −12.63% (below 0%: shrinking) 74.82% 12.82% Compare
VREX VAREX IMAGING $784.3M 34.7× 43.4× +3.69% (above 0%: growing) n/m +757.14% (above 0%: growing) 36.44% 10.83% Compare
CTKB Cytek Biosciences, Inc. $703.2M — (loss-making) — (loss-making) +5.57% (above 0%: growing) n/m +42.50% (above 0%: growing) 58.87% (23.68%)
PACB Pacific Biosciences of California, Inc. $609.2M — (loss-making) — (loss-making) −1.91% (below 0%: shrinking) n/m −30.97% (below 0%: shrinking) 32.40% (114.36%) Compare
KIDS OrthoPediatrics Corp. $589.3M — (loss-making) — (loss-making) +15.43% (above 0%: growing) n/m +77.59% (above 0%: growing) 74.27% (5.77%) Compare
TCMD Tactile Systems Technology, Inc. $527.6M 20.5× 22.7× +8.61% (above 0%: growing) +142.86% (above 0%: growing) −86.53% (below 0%: shrinking) 76.25% 7.97% Compare
Median of peers $804.2M 20.5× 18.0× +10.64% — −7.25% 66.66% (7.18%)

All 149 Medical Devices stocks →

Cytek Biosciences, Inc. (CTKB) key facts

  • Strength: Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024.
  • Cytek Biosciences, Inc. (CTKB) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CTKB traded at $5.24, a market capitalization of $703.2 million.
  • Return on equity was −18.1% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 3.89 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Cytek Biosciences, Inc. (CTKB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CTKB · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com